Antag Therapeutics

biotech · Copenhagen, DK

Copenhagen biopharma developing a GIPR antagonist for obesity.

Founders

Jens Holst (Denmark · ♂) — A University of Copenhagen professor renowned for discovering GLP-1, his decades of incretin-biology research and identification of an endogenous GIPR antagonist led him to co-found Antag to develop next-gen obesity therapies.
Mette Rosenkilde (Denmark · ♀) — A University of Copenhagen professor with deep incretin expertise, she co-discovered an endogenous GIPR antagonist with Jens Holst and co-founded Antag to advance a GLP-1 add-on obesity drug.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Dec 2024	Series A Antag Therapeutics raised an €80M Series A led by Versant Ventures to advance clinical development of its GIPR antagonist obesity therapy.	$84M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.